RU2556205C2 - Очищенные пирролохинолинил-пирролидин-2,5-дионовые композиции и способы их получения и применения - Google Patents

Очищенные пирролохинолинил-пирролидин-2,5-дионовые композиции и способы их получения и применения Download PDF

Info

Publication number
RU2556205C2
RU2556205C2 RU2012131344/04A RU2012131344A RU2556205C2 RU 2556205 C2 RU2556205 C2 RU 2556205C2 RU 2012131344/04 A RU2012131344/04 A RU 2012131344/04A RU 2012131344 A RU2012131344 A RU 2012131344A RU 2556205 C2 RU2556205 C2 RU 2556205C2
Authority
RU
Russia
Prior art keywords
pyrrolo
dihydro
dione
trans
indol
Prior art date
Application number
RU2012131344/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2012131344A (ru
Inventor
Дэвид П. РИД
Нил Р. БАРНС
Джон К. КЕЙН
Кристофер А. ЛИ
Цзянь-Се ЧЭНЬ
Мартин П. РЕДМОНД
Original Assignee
Аркьюл, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аркьюл, Инк. filed Critical Аркьюл, Инк.
Publication of RU2012131344A publication Critical patent/RU2012131344A/ru
Application granted granted Critical
Publication of RU2556205C2 publication Critical patent/RU2556205C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2012131344/04A 2009-12-23 2010-12-21 Очищенные пирролохинолинил-пирролидин-2,5-дионовые композиции и способы их получения и применения RU2556205C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28956309P 2009-12-23 2009-12-23
US61/289,563 2009-12-23
PCT/US2010/061625 WO2011079142A2 (en) 2009-12-23 2010-12-21 Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same

Publications (2)

Publication Number Publication Date
RU2012131344A RU2012131344A (ru) 2014-01-27
RU2556205C2 true RU2556205C2 (ru) 2015-07-10

Family

ID=44188284

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012131344/04A RU2556205C2 (ru) 2009-12-23 2010-12-21 Очищенные пирролохинолинил-пирролидин-2,5-дионовые композиции и способы их получения и применения

Country Status (19)

Country Link
US (3) US8552192B2 (OSRAM)
EP (2) EP2515904A4 (OSRAM)
JP (2) JP2013515737A (OSRAM)
KR (2) KR101669707B1 (OSRAM)
CN (2) CN102834097B (OSRAM)
AU (2) AU2010336533B9 (OSRAM)
BR (1) BR112012015656A2 (OSRAM)
CA (1) CA2785503A1 (OSRAM)
CO (1) CO6561823A2 (OSRAM)
HK (1) HK1215025A1 (OSRAM)
MX (1) MX2012007259A (OSRAM)
MY (2) MY169232A (OSRAM)
NZ (2) NZ628087A (OSRAM)
PH (2) PH12012501293A1 (OSRAM)
RU (1) RU2556205C2 (OSRAM)
SG (1) SG181927A1 (OSRAM)
TW (3) TWI506026B (OSRAM)
WO (1) WO2011079142A2 (OSRAM)
ZA (1) ZA201204759B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1846406T1 (sl) * 2005-02-09 2011-02-28 Arqule Inc Maleimidni derivati, farmacevtski sestavki in postopki za zdravljenje raka
CN102834097B (zh) * 2009-12-23 2015-06-17 艾科尔公司 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法
US9180099B2 (en) * 2011-07-07 2015-11-10 Arqule Inc. Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same
CN104379144A (zh) * 2012-04-23 2015-02-25 艾科尔公司 高度纯的吡咯并喹啉基-吡咯-2,5-二酮和吡咯并喹啉基-吡咯烷-2,5-二酮及其制备方法
EP3021849B1 (en) * 2013-07-16 2019-10-09 Dr. Reddy's Laboratories Ltd. Novel crystalline forms of pemetrexed tromethamine salts
DK3665176T3 (da) * 2017-08-11 2024-03-25 Actuate Therapeutics Inc Faste former af 3-(5-fluorbenzofuran-3-yl)-4-(5-methyl-5h[1,3]dioxolo[4,5-f]indol-7-yl)pyrrol-2,5-dion
CN110806454A (zh) * 2018-08-06 2020-02-18 江苏正大清江制药有限公司 一种盐酸吉西他滨中手性异构体的检测方法
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP2024513502A (ja) * 2021-04-07 2024-03-25 ユリカ セラピューティクス インコーポレイテッド Ｕｒａｔ１阻害剤、医薬組成物及びその使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2083580C1 (ru) * 1991-08-23 1997-07-10 Кали-Хеми Фарма ГмбХ 1,7-анеллированные производные 3-(пиперазиноалкил)-индола, способ их получения (варианты), содержащая их фармацевтическая композиция и промежуточный продукт для их получения

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5760237A (en) * 1995-08-25 1998-06-02 California Institute Of Technology Synthesis of l-azatyrosine using pseudoephedrine as a chiral auxiliary
EP1242420A2 (en) * 1999-12-16 2002-09-25 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
WO2004013069A1 (en) * 2002-07-31 2004-02-12 Firmenich Sa A process for the optical resolution of a precursor of sclareolide
EP1786772A1 (en) * 2004-09-10 2007-05-23 Wyeth a Corporation of the State of Delaware Process for the scalable synthesis of 1, 3, 4, 9-tetrahydropyranoý3, 4-b¨-indole derivatives
SI1846406T1 (sl) 2005-02-09 2011-02-28 Arqule Inc Maleimidni derivati, farmacevtski sestavki in postopki za zdravljenje raka
US20070185346A1 (en) * 2006-02-03 2007-08-09 Vaidya Niteen A Kit for automated resolving agent selection and method thereof
WO2009002807A2 (en) * 2007-06-22 2008-12-31 Arqule, Inc. Indolyl pyrrolidines for the treatment of cancer
CN101801961B (zh) 2007-06-22 2014-09-24 艾科尔公司 吡咯烷酮、吡咯烷-2,5-二酮、吡咯烷和硫代琥珀酰亚胺衍生物、组合物以及治疗癌症的方法
CN102834097B (zh) * 2009-12-23 2015-06-17 艾科尔公司 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法
CN104379144A (zh) * 2012-04-23 2015-02-25 艾科尔公司 高度纯的吡咯并喹啉基-吡咯-2,5-二酮和吡咯并喹啉基-吡咯烷-2,5-二酮及其制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2083580C1 (ru) * 1991-08-23 1997-07-10 Кали-Хеми Фарма ГмбХ 1,7-анеллированные производные 3-(пиперазиноалкил)-индола, способ их получения (варианты), содержащая их фармацевтическая композиция и промежуточный продукт для их получения

Also Published As

Publication number Publication date
NZ628087A (en) 2016-02-26
CO6561823A2 (es) 2012-11-15
EP3081567A3 (en) 2016-11-16
WO2011079142A2 (en) 2011-06-30
PH12012501293A1 (en) 2013-01-07
BR112012015656A2 (pt) 2016-05-10
MY169232A (en) 2019-03-19
RU2012131344A (ru) 2014-01-27
US8871933B2 (en) 2014-10-28
KR20160121602A (ko) 2016-10-19
US8552192B2 (en) 2013-10-08
JP2016041712A (ja) 2016-03-31
CA2785503A1 (en) 2011-06-30
TWI506026B (zh) 2015-11-01
ZA201204759B (en) 2014-03-26
US20140031551A1 (en) 2014-01-30
TW201141865A (en) 2011-12-01
AU2015243015B2 (en) 2017-02-02
WO2011079142A3 (en) 2011-11-24
EP3081567A2 (en) 2016-10-19
MY156701A (en) 2016-03-15
CN104910159A (zh) 2015-09-16
HK1215025A1 (zh) 2016-08-12
JP2013515737A (ja) 2013-05-09
AU2010336533B2 (en) 2015-09-10
US9499540B2 (en) 2016-11-22
EP2515904A2 (en) 2012-10-31
US20160024076A1 (en) 2016-01-28
TW201542546A (zh) 2015-11-16
AU2010336533B9 (en) 2015-10-08
NZ600800A (en) 2014-10-31
EP2515904A4 (en) 2013-07-03
CN102834097B (zh) 2015-06-17
KR101669707B1 (ko) 2016-10-27
MX2012007259A (es) 2015-05-15
AU2015243015A1 (en) 2015-11-05
AU2010336533A1 (en) 2012-07-12
SG181927A1 (en) 2012-07-30
PH12014500310A1 (en) 2015-09-28
TWI557125B (zh) 2016-11-11
US20110160242A1 (en) 2011-06-30
TW201643163A (zh) 2016-12-16
CN102834097A (zh) 2012-12-19
KR20120113760A (ko) 2012-10-15

Similar Documents

Publication Publication Date Title
RU2556205C2 (ru) Очищенные пирролохинолинил-пирролидин-2,5-дионовые композиции и способы их получения и применения
TWI615393B (zh) 丙烯酸類衍生物、其製備方法及其在醫藥上的用途
EP2720546B1 (en) Spiro-cyclic trpv4 antagonists
AU2025202754A1 (en) Imidazolonylquinoline compounds and therapeutic uses thereof
CN113710668B (zh) 用于ep300或cbp调节及其适应症的缩合吖嗪
EP4353724A1 (en) Compound as cdk kinase inhibitor and use thereof
EP4596553A1 (en) Salt of dioxane quinoline compound, crystal form thereof, preparation methods therefor and uses thereof
US20210340142A1 (en) Salt form and crystal form of novel azatricyclic compound and use thereof